Advertisement
A vs RGEN
Which Stock Would AI Choose? Agilent Technologies (A) vs. Repligen (RGEN) Stock Comparison
Key Takeaways
- A has delivered stronger recent price momentum, with gains exceeding 14% over the past month amid positive earnings surprises.
- RGEN reported solid Q2 2026 organic revenue growth of 13%, supported by bioprocessing demand, though its year-to-date return trails A.
- Both companies operate in the life sciences tools sector, with A offering broader analytical instrumentation exposure and RGEN focused on biopharmaceutical manufacturing solutions.
- A enters its Q3 earnings report on August 26 with raised full-year guidance, while RGEN maintains its fiscal 2026 growth outlook following recent results.
- Market sentiment favors both stocks, reflected in “Moderate Buy” and “Buy” consensus ratings, though relative performance highlights differences in short-term catalysts.
Introduction
Agilent Technologies (A) and Repligen Corporation (RGEN) represent two established players in the life sciences and bioprocessing tools industry. This comparison examines their business models, recent stock performance, and market positioning to assist traders and investors evaluating relative opportunities in the sector. The analysis draws on observable data from the past several weeks, providing context for those monitoring sector-specific trends, earnings catalysts, and momentum shifts without offering investment recommendations.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides analytical instruments, software, and services for laboratories across pharmaceuticals, diagnostics, and environmental testing. In recent weeks, the stock has shown notable strength, advancing more than 14% over the past month on the back of a second-quarter earnings beat and an upward revision to full-year guidance. The company reported revenue of approximately $1.83 billion in the prior quarter, exceeding expectations, with non-GAAP earnings per share (EPS) of $1.49. Upcoming third-quarter results scheduled for August 26 represent a key near-term catalyst, with analysts projecting $1.48 EPS and revenue near $1.84 billion. Broader market activity has supported sentiment around the stock’s consistent execution and diversified end-market exposure.
Repligen Corporation (RGEN) Overview and Recent Performance
Repligen Corporation specializes in bioprocessing products, including filtration systems and chromatography solutions used in biopharmaceutical manufacturing. Recent market activity reflects positive momentum following its second-quarter results, which showed organic revenue growth of 13% year-over-year to $204.1 million and an adjusted EPS beat. The company reiterated its full-year organic revenue growth guidance in the 9%–13% range while raising adjusted EPS targets. Over the past month, the stock has traded within a range influenced by sector rotation and analyst commentary, with year-to-date returns around 10.5%. Sentiment has been supported by ongoing demand in biologics production and operational improvements highlighted in recent filings.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the most suitable AI trading bots from hundreds available across thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions, consistent performance metrics, and appropriate risk profiles earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and performance statistics, with many showing win rates above 60% and varying drawdown levels in backtested or live environments. The platform enables users to explore tailored approaches suited to individual preferences. Review the Trending AI Robots page for current selections and detailed statistics.
Head-to-Head Comparison
Agilent Technologies maintains a broader business model encompassing life sciences, diagnostics, and applied markets, while Repligen focuses more narrowly on bioprocessing tools for drug manufacturing. Recent momentum favors A, with larger short-term gains tied to earnings delivery and guidance raises, compared with RGEN’s steadier but comparatively modest year-to-date advance. Both face sector exposure to healthcare spending and regulatory developments, yet A benefits from greater geographic and end-market diversification, potentially reducing volatility relative to RGEN’s concentration in biologics production. Risk factors include macroeconomic pressures on capital equipment spending for both, though RGEN’s growth outlook remains tied to biopharma pipeline activity. Market sentiment appears constructive for each, supported by analyst consensus ratings, with trade-offs centering on A’s scale versus RGEN’s specialized growth profile.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings execution, and near-term catalysts, Tickeron’s AI models currently assign a probabilistic edge to A over RGEN. Stronger recent price action, combined with an upcoming earnings release and prior guidance uplift, positions A with relatively favorable momentum characteristics in the current environment. RGEN demonstrates solid fundamentals and sector tailwinds but shows comparatively moderated short-term positioning. This assessment reflects pattern recognition across available data rather than a definitive outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and RGEN is a Hold.
| A | RGEN | A / RGEN | |
| Capitalization | 41.4B | 9.32B | 444% |
| EBITDA | 2.04B | 172M | 1,183% |
| Gain YTD | 8.630 | 0.806 | 1,071% |
| P/E Ratio | 28.98 | 226.22 | 13% |
| Revenue | 7.37B | 785M | 939% |
| Total Cash | 1.76B | 810M | 217% |
| Total Debt | 3.95B | 691M | 571% |
A | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 88 | |
PRICE GROWTH RATING 1..100 | 45 | 39 | |
P/E GROWTH RATING 1..100 | 42 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (11) in the Biotechnology industry is significantly better than the same rating for RGEN (83). This means that A’s stock grew significantly faster than RGEN’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGEN (100). This means that A’s stock grew similarly to RGEN’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for RGEN (88). This means that A’s stock grew somewhat faster than RGEN’s over the last 12 months.
RGEN's Price Growth Rating (39) in the Biotechnology industry is in the same range as A (45). This means that RGEN’s stock grew similarly to A’s over the last 12 months.
A's P/E Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for RGEN (100). This means that A’s stock grew somewhat faster than RGEN’s over the last 12 months.
| A | RGEN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 72% |
| Advances ODDS (%) | 17 days ago 60% | 19 days ago 74% |
| Declines ODDS (%) | 3 days ago 63% | 3 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 67% | N/A |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- RGEN’s TA Score: 4 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -2.61% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -1.44% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.54%. For the same industry, the average monthly price growth was +4.08%, and the average quarterly price growth was +36.27%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.51%. For the same industry, the average monthly price growth was -3.46%, and the average quarterly price growth was +12.67%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
RGEN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (-3.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-3.51% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | +0.30% | ||
| DHR - RGEN | 67% Closely correlated | -0.19% | ||
| A - RGEN | 65% Loosely correlated | +2.66% | ||
| BIO - RGEN | 60% Loosely correlated | +0.15% | ||
| MTD - RGEN | 59% Loosely correlated | +1.01% | ||
| TMO - RGEN | 58% Loosely correlated | +1.10% | ||
More | ||||